Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444684) titled 'A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Condition:
Pyoderma Gangrenosum
Intervention:
Drug: SHR-1139 Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 5, 2026
Target Sample Size: 20
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07444684
Published by HT D...